The anomalous pharmacology of fentanyl
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Fentanyl is a key therapeutic, used in anaesthesia and pain management. It is also increasingly used illicitly and is responsible for a large and growing number of opioid overdose deaths, especially in North America. A number of factors have been suggested to contribute to fentanyl's lethality, including rapid onset of action, in vivo potency, ligand bias, induction of muscle rigidity and reduced sensitivity to reversal by naloxone. Some of these factors can be considered to represent ‘anomalous’ pharmacological properties of fentanyl when compared with prototypical opioid agonists such as morphine. In this review, we examine the nature of fentanyl's ‘anomalous’ properties, to determine whether there is really a pharmacological basis to support the existence of such properties, and also discuss whether such properties are likely to contribute to overdose deaths involving fentanyls. LINKED ARTICLES: This article is part of a themed issue on Advances in Opioid Pharmacology at the Time of the Opioid Epidemic. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v180.7/issuetoc
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance
Williams, J. T., Ingram, S. L., Henderson, G., Chavkin, C., von Zastrow, M., Schulz, S., Koch, T., Evans, C. J., & Christie, M. J. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005942 · Cited by 802
Self-citationBias factor and therapeutic window correlate to predict safer opioid analgesics
Schmid, C. L., Kennedy, N. M., Ross, N. C., Lovell, K. M., Yue, Z., Morgenweck, J., Cameron, M. D., Bannister, T. D., & Bohn, L. M. (2017) · Cell · doi:10.1016/j.cell.2017.10.035 · Cited by 567 · cited 8×
“We know this to be true for fentanyl because depression of respiration is not observed in μ receptor knockout mice (Hill et al., 2020; Schmid et al., 2017).”
BackgroundInfluentialCould chest wall rigidity be a factor in rapid death from illicit fentanyl abuse?
Burns, G., DeRienz, R. T., Baker, D. D., Casavant, M., & Spiller, H. A. (2016) · Clinical Toxicology · doi:10.3109/15563650.2016.1157722 · Cited by 126 · cited 1×
“In overdose deaths involving illicit fentanyls, upper airway obstruction and respiratory muscle rigidity are likely to be significant factors (Burns et al., 2016).”
Background
Cited by
Molecular recognition of morphine and fentanyl by the human μ-opioid receptor
Zhuang, Y., Wang, Y., He, B., He, X., Zhou, X. E., Guo, S., Rao, Q., Yang, J., Liu, J., Zhou, Q., et al. (2022) · Cell · doi:10.1016/j.cell.2022.09.041 · Cited by 273
Clinical Pharmacokinetics and Pharmacodynamics of Naloxone
Saari, T. I., Strang, J., & Dale, O. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01355-6 · Cited by 77
Nunes, E. V., Comer, S. D., Lofwall, M. R., Walsh, S. L., Peterson, S., Tiberg, F., Hjelmstrom, P., & Budilovsky-Kelley, N. R. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.17377 · Cited by 25
Alhosan, N., Cavallo, D., Santiago, M., Kelly, E., & Henderson, G. (2025) · British Journal of Pharmacology · doi:10.1111/bph.17376 · Cited by 23
“Also, highly lipophilic agonists may be able to access the orthosteric pocket of the μ -opioid receptor both by the aqueous route and through the transmembrane helices of the receptor whilst naloxone uses only the aqueous route (Kelly et al., 2023; Sutcliffe et al., 2022).”
Self-citationPowers, N., Massena, C., Crouse, B., Smith, M., Hicks, L., Evans, J. T., Miller, S., Pravetoni, M., & Burkhart, D. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00347 · Cited by 15
Metadata
- Authors
- Kelly, E., Sutcliffe, K., Cavallo, D., Ramos‐Gonzalez, N., Alhosan, N., & Henderson, G.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2021-07-02
- Volume
- 180
- Issue
- 7
- Pages
- 797-812
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W3165836291
- Cited by
- 136
- References
- 3
- FWCI
- 15.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.